November 6, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Re: | Apellis Pharmaceuticals, Inc. |
| Registration Statement on FormS-1 |
| FileNo. 333-220941 |
| Request for Acceleration |
Ladies and Gentlemen:
In connection with the above-captioned Registration Statement, we wish to advise that between October 30, 2017 and the date hereof 2,814 copies of the Preliminary Prospectus dated October 30, 2017 were distributed as follows: 1,046 to institutional investors and 1,768 to prospective underwriters, dealers, individuals and others.
We have been informed by the participating underwriters that they will comply with the requirements of Rule15c2-8 under the Securities Exchange Act of 1934, as amended.
We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time, on November 8, 2017, or as soon thereafter as practicable.
[signature page follows]
Very truly yours,
Citigroup Global Markets Inc. | ||
| By: | /s/ Jennifer Fox | |
Name: Title: | Jennifer Fox Co-Head of North America Healthcare Group | |
J.P. Morgan Securities LLC | ||
| By: | /s/ David Ke | |
Name: Title: | David Ke Vice President | |
| Evercore Group L.L.C. | ||
| By: | /s/ Jonathan Alspaugh | |
Name: Title: | Jonathan Alspaugh Vice President | |
As Representatives of the several Underwriters
[SIGNATURE PAGE TO ACCELERATION REQUEST OF THE UNDERWRITERS]
